Nectar Lifesci.

{
  "main_header": {
    "sid": 216478,
    "name": "Nectar Lifesci.",
    "stock_name": "Nectar Lifesci.",
    "full_name": "Nectar Lifescience Ltd",
    "name_url": "stocks-analysis/nectar-lifesci",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "11.26",
    "chg": -0.42,
    "chgp": "-3.6%",
    "dir": -1,
    "prev_price": "11.68",
    "mcapval": "220.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532649,
    "symbol": "NECLIFE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE023H01027",
    "curr_date": "Jun 11, 03:30 PM",
    "curr_time": "01:34 AM",
    "last_traded_at": "Jun 11, 03:30 PM IST",
    "bse_nse_vol": "89.52 k",
    "exc_status": "Active",
    "traded_date": "Jun 11, 2026",
    "traded_date_str": "2026 06 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nectar-lifesci-216478-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nectar Lifescience Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-4046505",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_mojoScore_4046505.png",
        "date": "2026-06-11 10:10:22",
        "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Nectar Lifescience Ltd Reports Flat Quarterly Performance Amidst Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-ltd-reports-flat-quarterly-performance-amidst-margin-pressures-4030802",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_fintrenddot_4030802.png",
        "date": "2026-06-02 11:00:11",
        "description": "Nectar Lifescience Ltd reported a flat financial performance for the quarter ended March 2026, marking a notable improvement from previous negative trends but still reflecting significant operational challenges. Despite a stabilisation in revenue growth, the company’s profitability metrics deteriorated sharply, underscoring persistent margin pressures in a competitive pharmaceutical sector."
      },
      {
        "title": "Are Nectar Lifescience Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-nectar-lifescience-ltd-latest-results-good-or-bad-4028007",
        "imagepath": "",
        "date": "2026-06-01 19:23:49",
        "description": "Nectar Lifescience Ltd's latest financial results for Q4 FY26 reveal significant operational challenges and a concerning financial trajectory. The company reported a consolidated net loss of ₹67.92 crores, which marks a substantial deterioration compared to previous periods. Standalone results also reflect a net loss of ₹37.21 crores, a stark contrast to a profit of ₹0.30 crores in the prior quarter, indicating a severe decline in profitability.\n\nRevenue generation remains critically low, with standalone revenue reported at just ₹1.29 crores, showing minimal recovery from the previous quarter's ₹0.00 crores. This erratic revenue pattern raises questions about the company's operational stability and market demand for its products. The operating profit before depreciation, interest, and tax (PBDIT) fell to a record loss of ₹57.24 crores, illustrating a complete operational breakdown.\n\nThe company’s financial ..."
      },
      {
        "title": "Nectar Lifescience Q4 FY26: Mounting Losses Signal Deepening Operational Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/nectar-lifescience-q4-fy26-mounting-losses-signal-deepening-operational-crisis-4026922",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_quaterlyResult_4026922.png",
        "date": "2026-06-01 13:03:14",
        "description": "Nectar Lifescience Ltd., a micro-cap pharmaceutical company specialising in cephalosporins, reported a devastating quarter-on-quarter deterioration in Q4 FY26, with consolidated net losses ballooning to ₹67.92 crores—a staggering 575.96% increase from the previous quarter's ₹14.27 crore profit. The company's standalone net loss stood at ₹37.21 crores, marking a catastrophic reversal from operational stability and raising serious questions about the viability of its business model."
      },
      {
        "title": "Nectar Lifescience Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-4019994",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NectarLifescien_mojoScore_4019994.png",
        "date": "2026-05-29 10:10:22",
        "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Jul 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 29 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "When is the next results date for Nectar Lifescience Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-nectar-lifescience-ltd-4015096",
        "imagepath": "",
        "date": "2026-05-26 23:18:27",
        "description": "The next results date for Nectar Lifescience Ltd is scheduled for 30 May 2026...."
      },
      {
        "title": "Nectar Lifescience Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-ltd-hits-lower-circuit-amid-heavy-selling-pressure-3998637",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NectarLifescien_stocks_hitting_lower_circuit_3998637.png",
        "date": "2026-05-19 10:00:07",
        "description": "At Rs 11.77, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand."
      },
      {
        "title": "Nectar Lifescience Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-3996767",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NectarLifescien_mojoScore_3996767.png",
        "date": "2026-05-18 10:10:16",
        "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Nectar Lifescience Ltd Locks at Upper Circuit With 9.96% Gain — Buyers Queue, Sellers Absent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-ltd-surges-to-upper-circuit-amid-robust-buying-pressure-3981719",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NectarLifescien_stocks_hitting_upper_circuit_3981719.png",
        "date": "2026-05-08 12:00:06",
        "description": "At Rs 14.91, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 9.96% on 7 May 2026, with buyers queuing and no sellers willing to part with shares."
      }
    ],
    "total": 623,
    "sid": "216478",
    "stock_news_url": "https://www.marketsmojo.com/news/nectar-lifescience-216478"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Jun-2026",
      "details": "Please find attached herewith the copy of newspapers for publication of financial results of the Company for the quarter and financial year ended on March 31 2026",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Year 2025-26",
      "datetime": "30-May-2026",
      "details": "Financial Results for the Year 2025-26",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Audited Financial Results And Other Business Matters",
      "datetime": "25-May-2026",
      "details": "Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Audited Financial Results for the Financial Year 2025- 26 Financial Statement of the Company for the Financial Year 2025-26 and matters related thereto",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Nectar Lifescience Ltd has declared <strong>5%</strong> dividend, ex-date: 11 Sep 20",
          "dt": "2020-09-11",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Nectar Lifescience Ltd has announced <strong>1:10</strong> stock split, ex-date: 12 Nov 08",
          "dt": "2008-11-12",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Nectar Lifescience Ltd is Rated Strong Sell

2026-06-11 10:10:22

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Nectar Lifescience Ltd Reports Flat Quarterly Performance Amidst Margin Pressures

2026-06-02 11:00:11

Nectar Lifescience Ltd reported a flat financial performance for the quarter ended March 2026, marking a notable improvement from previous negative trends but still reflecting significant operational challenges. Despite a stabilisation in revenue growth, the company’s profitability metrics deteriorated sharply, underscoring persistent margin pressures in a competitive pharmaceutical sector.

Read full news article

Are Nectar Lifescience Ltd latest results good or bad?

2026-06-01 19:23:49

Nectar Lifescience Ltd's latest financial results for Q4 FY26 reveal significant operational challenges and a concerning financial trajectory. The company reported a consolidated net loss of ₹67.92 crores, which marks a substantial deterioration compared to previous periods. Standalone results also reflect a net loss of ₹37.21 crores, a stark contrast to a profit of ₹0.30 crores in the prior quarter, indicating a severe decline in profitability. Revenue generation remains critically low, with standalone revenue reported at just ₹1.29 crores, showing minimal recovery from the previous quarter's ₹0.00 crores. This erratic revenue pattern raises questions about the company's operational stability and market demand for its products. The operating profit before depreciation, interest, and tax (PBDIT) fell to a record loss of ₹57.24 crores, illustrating a complete operational breakdown. The company’s financial ...

Read full news article

Nectar Lifescience Q4 FY26: Mounting Losses Signal Deepening Operational Crisis

2026-06-01 13:03:14

Nectar Lifescience Ltd., a micro-cap pharmaceutical company specialising in cephalosporins, reported a devastating quarter-on-quarter deterioration in Q4 FY26, with consolidated net losses ballooning to ₹67.92 crores—a staggering 575.96% increase from the previous quarter's ₹14.27 crore profit. The company's standalone net loss stood at ₹37.21 crores, marking a catastrophic reversal from operational stability and raising serious questions about the viability of its business model.

Read full news article

Nectar Lifescience Ltd is Rated Strong Sell

2026-05-29 10:10:22

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Jul 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 29 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

When is the next results date for Nectar Lifescience Ltd?

2026-05-26 23:18:27

The next results date for Nectar Lifescience Ltd is scheduled for 30 May 2026....

Read full news article

Nectar Lifescience Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight

2026-05-19 10:00:07

At Rs 11.77, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

Read full news article

Nectar Lifescience Ltd is Rated Strong Sell

2026-05-18 10:10:16

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Nectar Lifescience Ltd Locks at Upper Circuit With 9.96% Gain — Buyers Queue, Sellers Absent

2026-05-08 12:00:06

At Rs 14.91, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 9.96% on 7 May 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

View All News